Global Amyotrophic Lateral Sclerosis (ALS) Market Size By Type (Riluzole, Edaravone (Radicava)), By Application (Hospital, Drugs Store), By Region, And Segment Forecasts, 2023 to 2032

The Global Amyotrophic Lateral Sclerosis (ALS) Market was valued at USD 738.4 million in 2023 and is projected to surpass USD 1.5 billion by 2031, growing at a CAGR of 9.3% during the forecast period from 2023 to 2031. The rising prevalence of ALS, increased awareness campaigns, expanding research into neurodegenerative diseases, and strong demand for disease-modifying treatments are among the key growth drivers of this market. Technological advancements in diagnostics, drug discovery, and the emergence of novel therapeutic approaches such as gene therapy and stem cell treatments are significantly reshaping the ALS treatment landscape.

Drivers:

1. Rising Incidence and Awareness of ALS:

ALS has a rising global incidence, especially among aging populations. Awareness initiatives led by non-profits, research institutions, and governments have improved early diagnosis and funding for ALS-related studies, increasing patient access to emerging therapies.

2. Growing R&D for Neurodegenerative Disorders:

Major pharmaceutical companies and biotech firms are intensifying research on ALS through clinical trials of novel drugs, regenerative treatments, and repurposed medications, driven by unmet medical needs and regulatory incentives like orphan drug designation.

3. Technological Advancements in Diagnostics and Imaging:

Modern neuroimaging, biomarkers, and AI-driven diagnostic tools are enhancing early and accurate detection of ALS. These technologies enable better tracking of disease progression and evaluation of therapeutic efficacy.

Restraints:

1. High Cost of Treatment and Limited Reimbursement:

ALS treatments, especially experimental therapies, are expensive and often lack adequate insurance coverage. This restricts accessibility, particularly in low- and middle-income countries.

2. Lack of Curative Therapies:

Despite active research, ALS remains incurable, with available treatments primarily focusing on symptom management. This limitation affects patient expectations and slows broader therapeutic adoption.

Opportunity:

1. Emergence of Gene and Stem Cell Therapies:

Promising breakthroughs in gene editing and stem cell-based therapies provide long-term growth opportunities. Several ongoing clinical trials focus on neuroprotective mechanisms to delay or reverse motor neuron degeneration.

2. Strategic Collaborations and Regulatory Incentives:

Collaborations between research institutions and biotech firms, along with orphan drug benefits and fast-track designations from regulatory agencies, are accelerating product development and commercialization pipelines.

Market by System Type Insights:

Based on therapeutic type, the medication segment dominated in 2023, driven by the continued use of Riluzole and Edaravone as FDA-approved treatments. However, the gene therapy segment is expected to witness the fastest growth due to robust clinical trial activity and rising investments in personalized medicine.

Market by End-use Insights:

Hospitals and specialized neurology clinics accounted for the largest market share in 2023. These facilities are central to diagnosis, monitoring, and treatment. The homecare segment is anticipated to grow significantly, fueled by telemedicine, remote monitoring technologies, and a shift toward outpatient management.

Market by Regional Insights:

North America led the global ALS market in 2023, supported by strong healthcare infrastructure, funding for research, and high patient awareness. The Asia-Pacific region is expected to register the fastest CAGR through 2031, driven by improving healthcare access, increasing diagnosis rates, and government initiatives in countries like Japan, China, and India.

Competitive Scenario:

Key players in the ALS market include Mitsubishi Tanabe Pharma Corporation, Amylyx Pharmaceuticals Inc., Ionis Pharmaceuticals, Inc., Biogen Inc., BrainStorm Cell Therapeutics Inc., and AB Science S.A. These companies are focusing on strategic licensing deals, expanding clinical trial portfolios, and novel therapy approvals. Notable developments include:

2023: Amylyx Pharmaceuticals received U.S. FDA approval for its ALS treatment AMX0035, which showed improved survival and functional outcomes.

2024: BrainStorm Cell Therapeutics advanced its stem cell therapy NurOwn into late-stage clinical trials after promising Phase II results.

2025: Biogen and Ionis Pharmaceuticals announced progress on their antisense oligonucleotide platform targeting SOD1 mutation-related ALS.

Scope of Work – Global Amyotrophic Lateral Sclerosis (ALS) Market

Report Metric Details

Market Size (2023) USD 738.4 million

Projected Market Size (2031) USD 1.5 billion

CAGR (2023–2031) 9.3%

Market Segments By Therapeutic Type, By End-use, By Region

Growth Drivers Rising prevalence, increased research funding, technological advances

Opportunities Gene/stem cell therapies, regulatory incentives,